glycine
Approved
May 25, 1976
Glycine (Cly) is a natural amino acid neurotransmitter that acts as a co-agonist at Glutamate [NMDA] receptors in the brain and is an activator of glycine receptors, GLRA1-3, GLRB. The abnormal Gly levels have been implicated in neuropsychiatric disorders. Alterations in Gly levels are implicated in several diseases of the central nervous system. Glycine was studied in phase II of clinical trials in patients with schizophrenia. The results have shown that using of glycine was associated with reduced symptoms with promising effect sizes and a possibility of improvement in cognitive function. Besides, glycine was also studied in clinical trials phase II in children with cystic fibrosis. The clinical, spirometric and inflammatory status of subjects with cystic fibrosis improved after just 8 weeks of glycine intake, suggesting that this amino acid might constitute a novel therapeutic tool for these patients. In addition, Gly was proposed as a biomarker for brain tumor malignancy. Glycine is a component of a nutrients mixture for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition. — NCATS
Clinical trial activity
43 trials · 42 clinical orgs · 5 marketing orgs
Earliest trial started Oct 1, 1997 (NCT00635102)
Timeline
1970s
1980s
- Feb 22, 1980
ICU Medical Inc — NDA Secondary Org
- May 30, 1980
Baxalta — NDA Secondary Org
- May 30, 1980
Baxter — NDA Secondary Org
1990s
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
- Aging · Phase 1
- Airway Management · Phase 2
- Alcoholism · Phase 2
- Alzheimer Disease · Early Phase 1
- Arthroplasty, Replacement, Knee · Phase 4
- Asthma · Phase 1/Phase 2
- Atherosclerosis · Phase 2/Phase 3
- Bipolar Disorder · Phase 2
- Cognitive Dysfunction · Early Phase 1
- COVID-19 · Phase 2
- Cystic Fibrosis · Phase 2
- Diabetes Mellitus · Phase 2/Phase 3
- Diarrhea · Phase 3
- Dyslipidemias · Phase 2/Phase 3
- Erythrocytes, Abnormal · Phase 1
- Fasting · Phase 1
- Growth Hormone · Phase 3
- Healthy Volunteers · Phase 1/Phase 2
- Herpes Labialis · Phase 2
- HIV Infections · Phase 1
- Hypertension · Phase 2
- Malnutrition · Phase 3
- Metabolic Syndrome · Phase 2/Phase 3
- Muscle Weakness · Phase 1
- Obesity · Phase 2/Phase 3
- Osteoarthritis, Knee · Phase 4
- Postoperative Pain · Phase 4
- Prader-Willi Syndrome · Phase 3
- Psychotic Disorders · Phase 2/Phase 3
- Schizophrenia · Phase 3
- Simplexvirus · Phase 2
Mechanism of action
- Glycine receptor (alpha-1/beta)SUBSTRATE
Glycine receptor (alpha-1/beta) substrate
Approval history
- approvedMay 25, 1976
- approvedMay 25, 1976
Chemistry & pharmacology
SMILES
NCC(O)=O- Mol. weight
- 75.0666 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlycine ↗
- NCATSTE7660XO1C ↗
- ChEMBLCHEMBL773 ↗
Also known as
- 2-aminoacetic acid
- aminoacetic acid
- aminoacetic acid
- aminoacetic acid
- aminoacetic acid
- aminoacetic acid
- aminoessigsäure
- aminoessigsäure
- aminoethanoic acid
- aminoethanoic acid
- gly
- gly
- glycin
- glycin
- glycine
- glycine
- glycine
- glycine
- glycine
- glycine
- glycine
- glycine
- glycine
- glycine
- glycine
- glycocoll
- glycocoll
- glycocoll
- glycolixir
- glycolixir
- glykokoll
- glykokoll
- glyzin
- glyzin
- leimzucker
- leimzucker
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07285135 | N/A | Dec 31, 2025 | Singapore General Hospital |
| NCT06959251 | N/A | Oct 2, 2025 | Instituto Nacional de Enfermedades Respiratorias |
| NCT06083480 | Phase 4 | Mar 31, 2024 | National Institute on Aging (NIA), Vanderbilt University |
| NCT06726902 | N/A | Mar 3, 2024 | Alexandria University |
| NCT05799521 | Phase 2 | Jun 27, 2023 | Indiana University |
| NCT06998160 | N/A | Jul 5, 2022 | Changsha Stomatological Hospital |
| NCT04740580 | Early Phase 1 (Phase 1) | Jul 1, 2021 | Baylor University, The University of Texas, Dallas |
| NCT04703036 | Early Phase 1 (Phase 1) | Jan 11, 2021 | Baylor University |
| NCT04658134 | N/A | Dec 15, 2020 | Baylor University, National University of Singapore, Singapore General Hospital |
| NCT04738422 | Phase 2 | Sep 11, 2020 | Indiana University |
| NCT04443673 | N/A | Aug 20, 2020 | Instituto Nacional de Enfermedades Respiratorias |
| NCT03850314 | Phase 2/Phase 3 (Phase 3) | Mar 31, 2019 | Technion University |
| NCT03617718 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | Case Western Reserve University, National Institutes of Health (NIH) |
| NCT03493178 | Early Phase 1 (Phase 1) | Apr 14, 2018 | Baylor University, The University of Texas, Dallas |
| NCT03353441 | N/A | Nov 15, 2017 | Daacro, MNPK BIOTIKI |
| NCT03166228 | Phase 2 | Jul 5, 2017 | Assiut University |
| NCT03154840 | Phase 1 | May 29, 2017 | LG |
| NCT04381026 | N/A | Apr 19, 2017 | Clínica Barem, Nektium Pharma SL |
| NCT02348762 | Phase 1 | Nov 1, 2014 | Baylor University |
| NCT02348775 | Phase 1 | Nov 1, 2014 | Baylor University |